Description: Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Home Page: www.frontagelab.com
700 Pennsylvania Drive
Exton,
PA
19341
United States
Phone:
610 232 0100
Officers
Name | Title |
---|---|
Dr. Song Li Ph.D. | Founder, CEO & Chairman |
Mr. Jianmin Wang | Chief Financial Officer |
Mr. Richard Fischetti J.D. | VP & Gen. Counsel of Frontage Labs |
Dr. Zhongping Lin Ph.D. | Exec. VP and Global Head of Bioanalytical & Biologics Services |
Dr. Dongmei Wang Ph.D. | Exec. VP for Global CMC Services |
Dr. Tianyi Zhang | Sr. VP of the Group & GM of Frontage Shanghai |
Dr. Abdul Ezaz Mutlib Ph.D. | Exec. VP |
Mr. Glenn Washer B.Sc., D.A.B.T, DABT | Pres of North America Operations |
Dr. Yining Qi M.D., M.P.H. M.B.A. | Pres of China Operations |
Mr. Sudendra Rao Ph.D. | Sr. VP of HR - North America |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
Forward PE: | 28.9855 |
---|---|
Trailing PE: | 33 |
Price-to-Book MRQ: | 1.8703 |
Price-to-Sales TTM: | 26.5334 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1505 |